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BACKGROUND The elimination of malaria depends on the blocking of transmission and of an effective treatment. In Brazil, 
artemisinin therapy was introduced in 1991, and here we present a performance overview during implementation outset years.
METHODS It is a retrospective cohort (1991 to 2002) of patients treated in a tertiary centre of Manaus, with positive microscopic 
diagnosis of Plasmodium falciparum malaria, under treatment with using injectable or rectal artemisinin derivatives, and 
followed over 35-days to evaluate parasite clearance, death and recurrence.
FINDINGS This cohort outcome resulted 97.6% (1554/1593) of patients who completed the 35-day follow-up, 0.6% (10/1593) of 
death and 1.8% (29/1593) of follow-up loss. All patients that died and those that presented parasitaemia recurrence had pure P. 
falciparum infections and received monotherapy. Considering patients who completed 35-day treatment, 98.2% (1527/1554) 
presented asexual parasitaemia clearance until D4 and 1.8% (27/1554) between D5-D10. It is important to highlight that had no 
correlation between the five treatment schemes and the sexual parasite clearance. Finally, it is noteworthy that we were able to 
observe also gametocytes carriage during all follow-up (D0-D35).
MAIN CONCLUSIONS Artemisinin derivatives remained effective in the treatment of falciparum malaria during first 12-years of 
use in north area of Brazil.
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Malaria is a major health problem in tropical and sub-
tropical regions of the world. According World Health Or-
ganization (WHO) 91 countries around the world present 
active malaria transmission, with a total of 445,000 deaths 
worldwide, of which 99% are caused by Plasmodium fal-
ciparum. In the Americas, malaria occurs in 21 countries, 
predominantly in South America, where four countries 
(Brazil, Colombia, Venezuela and Peru) account for more 
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than 70% of cases. In Brazil, most of the malaria cases are 
concentrated in the Amazon states (Acre, Amapá, Ama-
zonas, Maranhão, Mato Grosso, Pará, Rondônia, Roraima 
and Tocantins), an endemic area for the disease.(1)
Appropriate and early treatment is the basis of dis-
ease control, aiming at rapid cure in order to avoid the 
disease progress to severe forms and even death.(2) In 
this fight there is a vast and efficient therapeutic arsenal, 
however, despite the proven efficacy treatment failures 
are frequent and may be the result of drug resistance or 
inadequate exposure to drugs, whether due to failure in 
prescription and dispensing, incorrect dosage and even 
if the patient does not adhere to the treatment.(2,3) More-
over, resistance to antimalarial chemotherapy has been 
one of the major obstacle in the fight against this dis-
ease. The monitoring of the effectiveness of antimalarial 
drugs is a crucial component in the disease’s control, as 
the parasite develops mechanisms to avoid the action of 
antimalarial compounds.(4)
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Asexual forms of Plasmodium are responsible for the 
clinical manifestation of the disease, but its transmission 
occurs through the ingestion of sexual forms, gameto-
cytes, by a mosquito vector. Artemisinin-based combi-
nation therapies (ACTs) have recognised activity against 
immature gametocytes, but do not act against mature ga-
metocytes.(5) These residual gametocytes are often found 
in submicroscopic fractions, being a source of infection. 
However, microscopical examination is not sensitive 
enough to detect this small parasitological load and the 
molecular monitoring is extremely important because it 
detects extremely low densities of gametocytes.(6)
In Brazil, studies published in 1992 and 2010 have re-
ported resistance of P. falciparum to various compounds, 
such as chloroquine, sulfadoxine-pyrimethamine, meflo-
quine, quinine and amodiaquine.(7,8) Currently, ACT have 
been recommended as the first-line therapy for treating 
uncomplicated falciparum malaria in all endemic coun-
tries and failure of this P. falciparum therapy was not 
reported in Brazil.(9) In this therapy, the possibility of se-
lection of resistant parasites is decreased because most of 
the parasite load is eliminated by the rapid action of arte-
misinin and the residual parasitaemia is extinguished by 
the partner drug, which remains longer in circulation.(10)
The widespread diffusion of artemisinin treatment 
results in continuous pressure for the selection of the 
most resistant parasites and this is of great concern since 
there is no other pharmaceutical option as effective as 
artemisinin and its derivatives.(11,12) In 2008 and 2009 
studies developed on the Thai-Cambodian border, in 
Southeast Asia, already show a decrease in susceptibil-
ity of the P. falciparum to artemisinin. These studies re-
port a delay in the parasite clearance time in the blood of 
some patients, which suggests a change in the parasite’s 
susceptibility pattern to artemisinin and is probably the 
first sign of artemisinin resistance.(13,14,15) While in 2014, 
a report from French Guiana also point to a similar phe-
nomenon in Latin America.(16)
However, the efficacy of ACTs against P. falciparum 
malaria and absence of genetic markers associated with 
artemisinin resistance have been reported,(9) and accord-
ing to Worldwide Antimalarial Resistance Network in 
Latin America, there is no evidence that the protozoan’s 
resistance has reached in Brazil. Thus, the principal ob-
jective of our study was to determine the effectiveness 
of P. falciparum treatment with five artemisinin regi-
mens in the western Brazilian Amazon, by monitoring 
the parasitaemic clearance, death and recurrence during 
the follow-up period.
SUBJECTS AND METHODS
Study site - Our study was carried out at Fundação de 
Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), 
Manaus, in western Brazilian Amazon. FMT-HVD is a 
reference hospital for the diagnosis and treatment of tropi-
cal, infectious, parasitic and dermatological diseases.
Study design - This was a retrospective cohort study 
performed to assess the responses to artemisinin-based 
therapy regimens. Five groups of patients were constitut-
ed regarding the treatment regimens used, three of them 
as monotherapy (groups 1, 2 and 3) and two combined 
therapies (groups 4 and 5); group 1: artesunate (AS) IV 
1.5 mg/kg/day until D3; group 2: rectal artesunate sup-
positories (RAS), called a Rectocap™, at 50 mg/day D0 
until D4 for children; group 3: artemether (ATM) IM 
1.5 mg/kg/day until D3; group 4: artesunate IV 1 mg/
kg/day followed by oral mefloquine 20 mg/kg for 12/12 
hour at D2; and group 5: artemether IM 1 mg/kg/day un-
til D3, followed by oral mefloquine 20 mg/kg for 12/12 
hour at D2. Patients with mixed malaria, concomitance 
of P. falciparum and P. vivax, were treated with the same 
therapeutic schemes described above.
The data were grouped into two 6-year periods (sex-
enium), to compare all the evaluated variables. Asexual 
and sexual parasitaemia were monitored at admission 
(DO) and in the standardised days of follow-up: D1 to 
D7, D14, D21, D28 and D35.
Data collection - The data were collected by review-
ing all the registration forms over an 11-year period 
(September 1991 to December 2002) and transferred to 
a protocol specifically prepared for the study. The ex-
tracted data from these forms were: Plasmodium spe-
cies, parasite numbers, age, gender, artemisinin-based 
therapy and leukocytes count.
Inclusion criteria - Cases with parasitologically con-
firmed malaria caused by the single-species P. falci-
parum or mixed (P. falciparum plus P. vivax), which re-
ceived treatment with one of the five artemisinin-based 
regimens were enrolled in the study.
Criteria of exclusion - Patients with incomplete or 
illegible information, losses to follow-up and treatments 
with other types of antimalarial compounds or combina-
tions were excluded of the study.
Evaluation of the asexual and sexual parasitaemia 
and recurrence analysis - The parasite densities were 
quantified from thick blood films by counting the num-
ber of ring forms until 200 leukocytes were also count-
ed, and then multiplying the number found by 30, which 
assumes an average number of 6,000 leukocytes/µL. 
During treatment, the parasitaemia was registered daily 
until day 7 (D0 to D7) throughout hospitalisation and, 
after that, weekly until day 35 (D14, D21, D28 and 35). 
While, the gametocytaemia was evaluated in the diag-
nosis (D0) and at its appearance of gametocytes among 
the patients who did not have gametocytes at D0.
The “day-4” parasitaemia measure was considered 
a surveillance tool for artemisinin tolerance, guaran-
teeing the current WHO-recommended cut-off value 
(72 hours).(3,17)
The term recurrence was used to indicate the reap-
pearance of the asexual parasitaemia after its remission, 
during the 35-day follow-up. Here, we considered recur-
rence as recurrent asexual parasitaemia, after having 
observed its negativation, during the 35-day follow-up. 
Recurrence cases were carefully evaluated, regarding 
artemisinin treatment regimens, time and age groups by 
Kaplan-Meier analysis.
Statistical analysis - The enrolled patients were 
stratified into nine age groups (years): [a]:  ≤ 9; [b]: 10 
- 19; [c]:  20 - 29; [d]: 30 - 39; [e]: 40 - 49; [f]: 50 - 59; 
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[g]: 60 - 69; [h]: 70 - 79; and [i]: ≥ 80. The distribution 
of patients by year of admission, gender and age range 
was performed by the chi-square test. Comparison of the 
time for clearance and recurrence regarding age range, 
gender and treatment was analysed by Kaplan-Meier 
survival curves and by the log-rank test to compare the 
curves. All statistical tests were 2-tailed, and signifi-
cance was set up at p < 0.05. Statistical analysis was per-
formed using SAS, version 9.2 (SAS Institute).
RESULTS
Patients’ characteristics and epidemiological data 
- The flowchart of the study showed that the 2702 pa-
tients previously screened, 1109 of them were excluded 
(Fig. 1). Evaluation of all the patients showed that 97.6% 
(1554/1593) completed the 35-day follow-up [but 39 
(2.4%) did not: 10/1593 (0.6%) of them died and 29/1593 
(1.8%) lost the follow-up]. Of the 1593 eligible patients, 
229 received mefloquine in combination with artemis-
inin, and none of them evolved to death. The artesunate 
or artemether in monotherapy was administered to 1364 
patients, and 10 (0.7%) of them died before completing 
35-day follow-up, a higher incidence than that observed 
in combined therapy (p = 0.009).
The number of patients with mono-infection caused 
by P. falciparum was higher than those by P. falciparum 
plus P. vivax (p < 0.0001). The distribution regarding 
age groups showed significant differences (p < 0.0001), 
paying the attention the high prevalence of patients un-
der nine years old. These data are present in Table I. In 
these cases, the analysed variables were significant, ex-
cept for gender (p-value = 0.32).
The highest malaria occurrences were observed in 
the youngest age groups (p < 0.0001), with a substan-
tial increase in coinfection cases in age group 1 (one to 
nine years old) (Fig. 2-A); mono-infection was higher in 
all other age ranges. On the other hand, the coinfection 
showed a strong tendency to be higher (p = 0.06) in pa-
tients treated in the second sexenium than in the first one 
in early follow-up (Fig. 2B).
Progress of the asexual parasite during the 35-day 
follow-up - Considering patients who completed the 
35-day treatment with one of five analysed artemisinin-
based regimens, 98.2% (1527/1554) presented asexual 
parasitaemia clearance until D4 and only 1.8% (27/1554) 
between D5-D10 (Table II). These results revealed only 
three patients (0.2%) with negative parasitaemia be-
tween D7 and D10.
The Fig. 3 presents the comparison of the time for 
clearance of asexual parasite regarding to five artemis-
inin-based regimens (Fig. 3A), age groups (Fig. 3B) and 
gender (Fig. 3C) generated by the Kaplan-Meier survival 
plot. All analysed variables indicated statistical differ-
ences (p-value ≤ 0.05). However, when we separating 
cases of mono-infection and coinfection, we did not find 
any statistical correlation of asexual parasite clearance 
rates with different artemisinin-based therapies, age and 
gender (data not shown).
Fig. 1: flowchart of the study.
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Progress of the sexual parasite during the 35-day 
follow-up - The analysed sexual stage indicated preva-
lence of gametocytes in 47% (748/1593) of enrolled pa-
tients, 26.2 % (196/748) of whom presented gametocytes 
at enrollment (day 0), compared to 73.7% (552/748) who 
exhibited sexual stage at least once during the 35-day 
follow-up (Table III). Among the individuals who ex-
hibited sexual parasitaemia, just age groups (p-value 
= 0.003) and gender (p-value < 0.001) revealed signifi-
cant correlation with gametocyte clearance (p-values = 
0.003) (Fig. 4). It is important to highlight that had no 
correlation between the five treatment schemes and the 
sexual parasite clearance during this cohort (Fig. 4A).
Parasitaemia recurrence during the follow-up - Re-
garding parasitaemia recurrence in patients treated with 
monotherapy, 4.9% with RAS, 1.6% with AS IV and 
0.3% with ATM IM demonstrated recurrence of para-
sitaemia during follow-up. In the other hand, patients 
treated with combined therapy (ASMQ and ATMMQ) 
did not present reappearance of the parasitaemia during 
the follow-up. Although the statistical analysis revealed 
no association with treatment regimen (p-value = 0.06), 
age (p-value = 0.85) or time treatment (p-value = 0.65).
DISCUSSION
This is a 12-year retrospective analysis on the suscep-
tibility of P. falciparum to artemisinin based-therapies 
among hospitalised patients to treatment in the Northern 
Brazilian region, after its introduction in 1991. Almost 
all hospitalised patients who completed the 35-day fol-
low-up period presented good therapeutic response with 
negative parasitaemia, thus demonstrating the treatment 
regimen effectiveness. This finding is very important 
because the control and elimination of falciparum ma-
laria depends not only on the blocking of transmission 
but also on the provision of an effective treatment.(18,19)
TABLE I
Comparative epidemiological profile between infection types (1991 to 2002)
Variables
Plasmodium falciparum P. falciparum plus P. vivax
Total (%) p-value*Number of cases
Number of patients 1432 161 1593 (100) < 0.0001
Age groupa
< 0.0001
1 391 73 464 (29)
2 191 18 209 (13)
3 261 22 283 (18)
4 156 15 171 (11)
5 114 7 121 (8)
6 71 7 78 (5)
7 54 3 57 (4)
8 13 5 18 (1)
9 181 11 192 (12)
Gender 
0.32male 803 83 886 (56)
female 623 76 699 (44)
Year 
0.006
1991 28 2 30 (2)
1992 44 4 48 (3)
1993 103 3 106 (7)
1994 92 5 97 (6)
1995 114 24 138 (9)
1996 154 18 172 (11)
1997 119 13 132 98)
1998 169 13 182 (11)
1999 311 38 349 (22)
2000 156 26 182 (11)
2001 63 3 66 (4)
2002 79 12 91 (6)
a: the enrolled patients were stratified prospectively into nine age groups: 1 = ≤ nine years; 2 = 10-19 years; 3 = 20-29 years; 
4 = 30-39 years; 5 = 40-49 years; 6 = 50-59 years; 7 = 60-69 years; 8 = 70-79 years and 9 = older than 80 years. * chi square test.
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This study found malaria occurrence was higher in 
the youngest age groups, with a substantial increase of 
mixed malaria between one to nine years old. In this 
sense, is important to highlights that usually, manu-
scripts about treatment of hospitalised patients with 
malaria presents high frequency of children. However, 
in our study there were no predominance of children 
among the analysed patients, because all of them were 
admitted to the hospital to treatment because the recom-
mended protocol of the Service.
Artemisinin-based therapies rapidly (~ 2 days) clear 
the asexual parasitaemia, which are responsible for the 
clinical picture, rendering this medication the choice for 
the treatment of falciparum malaria. This study showed 
more than 75% reduction in asexual parasitaemia clear-
ance rates during the first three days of treatment, reach-
ing 98.3% until D4. Delayed negative asexual parasitae-
mia, between D5 and D10, was observed in only 1.7% of 
the cases. The delay of the asexual parasitaemia clear-
ance, by itself, can suggest resistance to this compound, 
but does not necessarily indicates failure of the artemis-
inin treatment;(13) it is also necessary to detect associated 
genetic mutations. However, the K13 polymorphism 
had not been detected in P. falciparum parasites from 
Brazilian endemic areas.(20) Taken together, our findings 
and those from Gomes et al.(20) make us to suppose that 
there is no evidence of declining artemisinin-regimen 
effectiveness in northern Brazil during the first decade 
of its use. Although worldwide there have been reports 
of decreased artemisinin-derivative susceptibility,(21,22) 
sensitivity of P. falciparum and treatment effectiveness 
remain high in Brazil.(23) It is important to register that 
Fig. 2: distribution of case numbers according to age range groups 
and year. Results were considered statistically significant when p-
values were ≤ 0.05 by chi-square test. (A) (p-value < 0.0001). (B) 
(p-value = 0,006).
TABLE II
Asexual parasite clearance profile during 35-day follow-up (1991 to 2002)
Follow-up (days)a
AS ASMQ ATM ATMMQ RAS Total
No. % No. % No. % % No. % %
D1 163 16.9 12 8.9 31 9.7 4 4.3 8 18.6 14
D2 517 53.5 69 51.1 153 48.1 35 38 25 58.1 51.4
D3 210 21.7 39 28.9 98 30.8 40 43.5 5 11.6 25.2
D4 60 6.2 13 9.6 31 9.7 11 12 3 7 7.6
Subtotal 
(D0-D4) 950 98.3 133 98.5 313 98.4 90 97.8 41 95.3 98.3
D5 12 1.2 1 0.7 4 1.3 1 1.1 1.2
D6 2 0.2 1 0.3 2 4.7 0.3
D7 1 0.1 0.1
(D7-D10) 1 0.1 1 0.7 1 1.1 0.2
Subtotal 
(D5-D10) 16 1.7 2 1.5 5 1.6 2 2.2 2 4.7 1.7
Total 
(D0-D35) 966 62.2 135 8.7 318 20.5 92 5.9 43 2.9 100
a: follow-up days: of treatment: D: day; 0-day (D0) at baseline treatment, 1-day until 7-day (D1, D2, D3, D4, D5, D6 and D7), 
14-day (D14), 21-day (D21), 28-day (D28) and 35-day (D35). AS: artesunate; ASMQ: artesunate plus mefloquine; ATM: artemether; 
ATMMQ: artemether plus mefloquine; RAS: rectal artesunate suppositories.
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the control of the clearance of the asexual parasitaemia 
is a tool to evaluate the emergence of P. falciparum re-
sistance to antimalarial compounds.
Although artesunate monotherapy was highly effec-
tive in clearing asexual blood-stage parasitaemia, a good 
response was also observed with the ASMQ treatment. 
Similar clearance to this combination therapy was previ-
Fig. 3: comparison of the time for clearance of asexual parasite regarding to five artemisinin-based regimens (Fig. 3A), age groups (Fig. 3B) and 
gender (Fig. 3C) generated by the Kaplan-Meier survival plot.
TABLE III
Prevalence of sexual parasite (gametocytes)  
during 35-day follow-up (1991 to 2002)
Number of patients 
with gametocytes














a: follow-up days of treatment: D: day; 0-day (D0) at baseline 
treatment, 1-day until 7-day (D1, D2, D3, D4, D5, D6 and D7), 
14-day (D14), 21-day (D21), 28-day (D28) and 35-day (D35).
ously reported in the Peruvian Amazon.(24) In addition, 
Ladeia-Andrade et al.(9) defined the use of ASMQ fixed-
dose combination as the first-line regimen to treat P. fal-
ciparum in the Juruá Valley, a Brazilian region with high 
transmission of P. falciparum, where the authors showed 
no molecular evidence of resistance to AS and MQ dur-
ing the 2010 to 2013 period.
It is worth mentioning that these results reflect the 
first decade of artemisinin-based therapy use in north-
ern Brazil, and current monitoring should be performed 
to evaluate the present situation in the region. Studies 
using artemether(25) and artesunate(26) monotherapy in 
Suriname, published in 2013 and 2016 respectively, a 
neighboring region from Brazil, raised the suspicion of 
resistance to this compound.
In addition, several studies have reported P. falci-
parum resistance to artemisinin derivatives in southeast 
Asia, which is of great concern, as there is no alternative 
as effective as artemisinin, and the spread of resistance 
throughout the world would be catastrophic.(17,25) This 
study compared the efficacy of artemether-lumenfan-
trine, evaluating the clearance of parasitaemia up to D3, 
with another study conducted in the period 2005-2006 to 
detect the appearance of resistance to artemether. Find-
ings may represent emerging resistance of Plasmodium 
to artemether in a country outside the emerging region 
of resistance, Asia, which causes great concern because 
it is an area with a history of malaria infection, and also 
because it is a gold mining area.(25)
Although the main focus is the asexual parasitaemia, 
because it is responsible for the clinical symptoms of the 
disease, we also analysed the presence at admission and 
the emergence of sexual forms during the follow-up. The 
gametocyte is the transmission form from human host to 
mosquitoes.(6) Therefore, the understanding of the influ-
ence of gametocytaemia and gametocidal properties of 
antimalarial compounds is of great relevance for actions 
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Fig. 4: comparison of the time for clearance of sexual parasite (gametocytes) regarding to five artemisinin-based regimens (Fig. 4A), age groups 
(Fig. 4B) and gender (Fig. 4C) generated by the Kaplan-Meier survival plot.
aimed at reducing malaria transmission. Herein, we ob-
served a relatively high proportion, 47% (748/1,593), of 
individuals with gametocytes, but there was no correla-
tion between the different treatment regimens and sex-
ual parasitaemia clearance. On the other hand, overall, 
12.3% of enrolled patients had gametocytaemia at ad-
mission, and this gametocyte presence at early phase of 
treatment (day 0) seems to influence the malaria clear-
ance (data not show).
It is noteworthy that in our cohort we were able also 
to observe sexual parasitaemia after D3 until D35. Ar-
temisinin and its derivatives do attenuate the growth of 
young parasites in vitro and increase the clearance of ring 
forms in vivo. The artemisinin derivatives are a first-line 
antimalarial compounds that act only on the early stage 
of the gametocytes. Thus, in combined therapies the 
sexual parasitaemia clearance depends on mefloquine, 
since this antimalarial compound is cleared slowly as 
its half-life elimination is two to three weeks.(27) This 
finding can explain the increased gametocyte carriage 
during treatment, to be removed in the third and subse-
quent post-treatment replication cycles.(28) So, as game-
tocytes are the forms that are taken up by and infect the 
anopheline mosquitoes, to maintain the Plasmodium life 
cycle, artemisinin and its derivatives do not prevent this 
transmission.(29) This is an important finding for public 
health, as the effect of antimalarial compounds in reduc-
ing gametocyte carriage plays a role in malaria control. 
For information purposes, although primaquine was not 
evaluated in this study because it was an exclusion cri-
teria, during the period of the study of this cohort, there 
was already a national recommendation for its use with 
aim of eliminating the gametocytes.
Several factors may have contributed to recurrence, 
observed only in patients receiving artemisinin-deriva-
tive monotherapy. Noncompliance could explain these 
treatment failures, however the dispensing of drugs was 
assisted because the enrolled patients were hospitalised 
during their follow-up. In addition, the deaths were ob-
served only in the group of patients with pure P. falci-
parum infection receiving artemisinin-derivative mono-
therapy. Thus, our results suggest that the combined 
therapy with mefloquine prevented recurrences and 
deaths, possibly because mefloquine remains longer in 
the bloodstream due to its greater elimination half-life, 
in contrast to artemisinin derivatives that are rapidly 
eliminated (half-life about 16 hours).
Among the patients who did not progress to death, 
93% presented negative asexual parasitaemia after treat-
ments. Differently, all patients who progress to death 
presented positive asexual parasitaemia until the last day 
of life and died until D7. So, even though the parasitae-
mia at D0 was lower in patients who died (4,080/µL) than 
those who surveilled (15,647/µL), it had been persistent. 
In addition, 30% of patients who died (3/10) presented 
gametocytes at admission compared to all enrolled pa-
tients (12.3%).
Co-infection with P. vivax was detected in 10% of 
the enrolled patients, which increased over the years, 
since a greater number of cases were observed in the 
second sexenium. In the last decade, the world has seen 
a significant decline in the number of malaria cases, 
accompanied by an increase of malaria vivax / malaria 
falciparum ratio. Mohapatra et al.30) demonstrated that 
P. vivax infection may be protective when coexisting 
with P. falciparum, with less severe disease and a lower 
level of parasitaemia than it was observed in infections 
caused only by P. falciparum.(30)
Ethics approval and consent to participate - The 
study was in accordance with the ethical standards of 
the declaration of Helsinki and approved by the institu-
tion’s ethics committee (CEP/FMT-HVD CAAE num-
ber: 46481215.2.0000.0005).
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In conclusion - In spite of the limitations, because it is 
a retrospective study involving observation for a long pe-
riod of time and with information retrieved from medical 
record books, this study is the largest series of cases with 
patients treated with artemisinin-based therapies, which 
have already been described in the Amazon Region. This 
study showed stable levels of P. falciparum sensitivity 
to artemisinin derivatives in the Amazon Region over 
a period of 12 years. In conclusion, our findings do not 
evidence the occurrence of P. falciparum resistance to 
artemisinin derivatives in the assessed period; however, 
routine monitoring of artemisinin should continue, so that 
the first signs of resistance are detected early.
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